Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection.

Abstract

The immunogenicity and safety profile of an inactivated whole-virion influenza A (H5N1, NIBRG-14) vaccine with alum adjuvant that was administered by IM or SC injection in a phase I clinical study involving 120 healthy Japanese men aged 20-40 years is described. The serological response of the IM group was stronger than that of the SC group. Local adverse events were less severe with IM injection than with SC injection, while similar systemic adverse events were seen in both groups. These results indicate that, when administering an inactivated whole virion vaccine with alum adjuvant for pandemic influenza, IM injection may achieve better immunogenicity and safety than SC injection.

• Authors: Daisuke Ikeno, Kazuhiko Kimachi, Yoichiro Kino, Seiichi Harada, Kayo Yoshida, Shinji Tochihara, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro, Kenji Okada, Chiaki Miyazaki, Kohji Ueda
• Journal: Microbiology and immunology (Microbiol Immunol) Vol. 54 Issue 2 Pg. 81-8 (Feb 2010) ISSN: 0385-5600 [Print] Australia
• PMID: 20377741 (Publication Type: Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial)

Chemical References

• Adjuvants, Immunologic
• Antibodies, Viral
• Influenza Vaccines

Topics

• Adjuvants, Immunologic (administration & dosage, adverse effects)
• Adult
• Antibodies, Viral (blood)
• Female
• Humans
• Influenza A Virus, H5N1 Subtype (immunology)
• Influenza Vaccines (administration & dosage, adverse effects, immunology)
• Influenza, Human (immunology, prevention & control, virology)
• Injections, Intramuscular
• Injections, Subcutaneous
• Male
• Virion (immunology)
• Young Adult